Polatuzumab vedotin
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | CD79B |
| Identifiers | |
| CAS Number | 1313206-42-6 |
| ATC code | none |
| IUPHAR/BPS | 8404 |
| Chemical data | |
| Formula | C6670H10317N1745O2087S40 |
| Molecular mass | 149.6 kg/mol |
Polatuzumab vedotin[1] (RG7596) is a monoclonal antibody designed for the treatment of cancer.[2]
This drug was developed by Genentech/Roche.
A phase 1 clinical trial in B-cell non-Hodgkin’s lymphoma is registered.[3]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Polatuzumab Vedotin, American Medical Association - Needs login/subscription.
- ↑ NCT01992653 (Clinical Trial / Polatuzumab Vedotin / DCDS4501A / RG-7596)
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibodies
- Monoclonal antibody stubs
